Karl is originally from Ontario, Canada. He graduated as a geneticist from Melbourne University in Australia and obtained his PhD in circadian genomics from the Erasmus Medical Center (EMC) in Rotterdam, The Netherlands. A subsequent post-doctoral fellowship within the Dept. of Bioinformatics, EMC supported by the Dutch Center for Translational Molecular Medicine identified predictive biomarkers in patients with heart disease through commercial partnering of both clinical and basic research. At Bayer since 2015, he uses his experience with open source and contemporary digital tools and frameworks to drive digital innovation around clinical trial data towards faster, deeper, trustful insights on behalf of the patient.